Biosimilar Antibodies

Zimberelimab (GLS-010) is a fully human monoclonal antibody of the IgG4 subclass that targets PD-1 with a high affinity, demonstrated by an EC50 of 210 pM. This antibody effectively inhibits the interaction between PD-1 and its ligands PD-L1 and PD-L2, with IC50 values of 580 pM and 670 pM respectively, in CHO-S cell assays. Zimberelimab has been shown to exhibit potent antitumor activities. It is applicable in the research of various cancers, including cervical cancer, non-small cell lung cancer, and classical Hodgkin’s lymphoma, making it a valuable tool for oncological studies focused on immune checkpoint pathways.

Apolizumab (Hu1D10) is a humanized monoclonal antibody targeting the Human Leukocyte Antigen-DR beta-chain (HLA-DR beta-chain). This antibody has demonstrated the capability to mediate apoptosis in chronic lymphocytic leukemia (CLL) cells in vitro, suggesting its potential utility in research focused on the mechanisms of CLL pathology and therapeutic interventions.

Latozinemab (AL001) is a recombinant human monoclonal antibody targeting Sortilin. It binds with high affinity to Sortilin, effectively inhibiting the interaction between the progranulin protein (PGRN) and the Sortilin receptor. This antibody is particularly relevant for research into mutations in the progranulin gene (GRN) that are implicated in the pathogenesis of Frontotemporal Dementia (FTD-GRN), offering potential insights into therapeutic interventions and disease mechanisms.

Ecromeximab, also known as KM 871 and KW 2871, is a chimeric monoclonal antibody of the IgG-κ isotype derived from mouse. It specifically targets ganglioside GD3, a sialic acid-containing glycosphingolipid overexpressed in various tumor cells. This antibody is produced in YB2/0 rat hybridoma cells, ensuring a high level of purity and specificity. Ecromeximab is utilized primarily in research focused on the therapeutic targeting of cancers that express ganglioside GD3.

Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal antibody that targets the interleukin-2 receptor. This antibody is specifically designed for research applications focusing on renal transplantation, providing a valuable tool for investigating immune response modulation in this context.

Faralimomab (64G12) is a murine-derived monoclonal antibody of the IgG1 subtype that targets interferon-alpha 1 (IFNA1). It functions as an immunomodulator by binding to IFNA1, thereby potentially modulating immune responses mediated by this cytokine. Faralimomab is utilized in research settings to study the role of IFNA1 in immune regulation and its implications in various inflammatory and autoimmune disorders.

The Anti-MAGEC2/CT10 Antibody (LX-CT10.5) is a chimeric mouse monoclonal antibody of the IgG2a, κ subtype, designed to specifically target human MAGEC2/CT10. For accurate isotype control in experimental procedures, it is recommended to use the Mouse IgG2a kappa, Isotype Control.

Samatatug is a human monoclonal antibody of the IgG1κ subtype that specifically targets the F3 protein. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

AFM24 is a bispecific TandAb antibody, produced in Chinese Hamster Ovary (CHO) cells, designed to target both EGFR and Fc-gamma-RIIIA. This antibody comprises a human IgG1-SCFV heavy chain paired with a λ light chain, and has a predicted molecular weight of 74.5 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. AFM24 is applicable in research focusing on the modulation of immune responses and the investigation of EGFR-related signaling pathways in oncology.

Varokibart (TEV-53275) is a humanized IgG4λ monoclonal antibody designed to specifically target and neutralize interleukin 5 (IL-5). This antibody is engineered for stability and reduced immunogenicity, making it an ideal tool for research focused on the role of IL-5 in eosinophilic disorders and other inflammatory conditions.

The Anti-IGFBP2 Antibody (M14) is a human monoclonal antibody that exhibits high-affinity binding to insulin-like growth factor-binding protein 2 (IGFBP2). This antibody effectively inhibits the interaction between IGFBP2 and insulin-like growth factor 1 (IGF1), thereby blocking IGFBP2's biological activity. The Anti-IGFBP2 Antibody (M14) has been demonstrated to inhibit endothelial cell recruitment, a critical process in tumor angiogenesis and metastasis, thereby impeding the progression of human metastatic cancers. This product is pivotal for research focused on cancer biology, particularly in studies exploring mechanisms of tumor growth and metastasis.

Etokimab, also known as Antibody ANB 020, is a humanized monoclonal antibody specifically designed to target interleukin-33 (IL-33). This antibody is utilized primarily in the study of atopic dermatitis, providing a valuable tool for researchers investigating the pathophysiological mechanisms and potential therapeutic interventions for this condition.

Amdokitug is a human IgG1 κ monoclonal antibody targeting IL-17A. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody designed to specifically target HER3. This antibody effectively inhibits the activation of members of the epidermal growth factor receptor (ErbB) family and their downstream signaling pathways. Seribantumab has demonstrated the ability to suppress neuregulin 1 (NRG1) fusion-dependent tumorigenesis both in vitro and in vivo, showing efficacy in patient-derived models of breast, lung, and ovarian cancers. This makes it a valuable tool for research in cancer biology, particularly in studies focusing on the molecular mechanisms of tumorigenesis and therapeutic antibody development.

Anti-Clusterin (AB-16B5) is a humanized IgG2 monoclonal antibody specifically designed to target clusterin, a key protein involved in the regulation of the epithelial to mesenchymal transition (EMT). This antibody functions as an inhibitor of EMT, a process frequently implicated in cancer progression and metastasis. Anti-Clusterin (AB-16B5) is primarily utilized in oncological research studies to explore clusterin's role in cancer biology and its potential as a therapeutic target.

ADG-106 is a fully human agonistic monoclonal IgG4 antibody targeting CD137 (4-1BB). This antibody is designed to activate CD137 through potent FcγRIIB-mediated crosslinking, concurrently antagonizing CD137 ligands. For isotype control purposes, Human IgG4 (S228P) kappa, Isotype Control is recommended. This product is pivotal in studies focused on the modulation of immune responses, particularly in the context of immunotherapy and cancer research.

Tildrakizumab (SCH 900222) is a humanized monoclonal antibody selectively targeting the p19 subunit of interleukin-23 (IL-23), a pivotal cytokine in sustaining the Th17 cell phenotype. This antibody exhibits high affinity for the single-chain IL-23, demonstrated by a dissociation constant (Kd) of 136 pM. Clinically, Tildrakizumab has been shown to be effective in the treatment of moderate to severe plaque psoriasis.

Indenebart is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets SNCA (alpha-synuclein). For accurate experimental control, it is recommended to use Human IgG1 lambda2 as an isotype control. This antibody is ideal for research focused on the pathological roles of alpha-synuclein, including its implications in neurodegenerative disorders such as Parkinson's disease.

Obexelimab (XmAb5871) is a humanized monoclonal antibody targeting CD19, a protein expressed on the surface of B cells. This antibody functions by inhibiting the B cell receptor (BCR)-mediated calcium influx and enhancing the phosphorylation of Fcγ receptor IIb (FcγRIIb). These actions collectively diminish B cell activation and functionality, ultimately inducing B cell apoptosis. Obexelimab is primarily utilized in research studies focusing on autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these conditions.

Foravirumab (CR4098) is a monoclonal antibody specifically targeting antigenic site III of the rabies virus glycoprotein. This antibody is designed for precise binding to the rabies virus, facilitating further research into viral mechanisms and potential therapeutic interventions.

Azintuxizumab is a human IgG4κ monoclonal antibody targeting SLAMF7. It is designed for use in the development of antibody-drug conjugates, specifically Azintuxizumab vedotin. This antibody is engineered for precise binding to the SLAMF7 antigen, making it a critical component in targeted cancer therapy research.

Eurestobart is a humanized IgG1 kappa monoclonal antibody specifically designed to target ectonucleoside triphosphate diphosphohydrolase (ENTPDase). This antibody is engineered for high specificity and affinity in binding to its antigen, making it suitable for a variety of research applications focusing on the role of ENTPDase in disease processes and therapeutic interventions.

Fontolizumab (HuZAF) is a humanized monoclonal antibody that targets interferon-gamma (IFN-γ), serving as an immunosuppressive agent. This antibody is specifically designed for the study of immune response mechanisms in conditions such as Crohn’s disease, providing a valuable tool for researchers investigating the pathophysiology and potential therapeutic interventions for this inflammatory bowel disease.

Sotrovimab (VIR 7831) is a human IgG1κ monoclonal antibody designed to target and neutralize a broad range of sarbecoviruses, including SARS-CoV-2 and SARS-CoV-1. This antibody is derived from S309, a precursor known for its potent neutralizing capabilities. Sotrovimab features an extended half-life and enhanced bioavailability, particularly within the respiratory mucosa. Its mechanism of action facilitates the clearance of virus-infected cells and is effective in preventing the progression of COVID-19 when administered early in the disease course. This makes Sotrovimab a valuable tool in therapeutic interventions against COVID-19 and related coronavirus infections.

The Anti-TSHR Antibody (K1-70) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the Thyroid Stimulating Hormone Receptor (TSHR), making it an essential tool for research in thyroid function and autoimmune thyroid diseases. This antibody is comprised of a human IgG1 heavy chain and a human lambda light chain, and has a predicted molecular weight of 143.54 kDa. For experiments requiring an isotype control, the Human IgG1 kappa, Isotype Control is recommended to accurately assess the specificity and binding characteristics of the Anti-TSHR Antibody (K1-70).

The Anti-IL-5 Antibody is a humanized antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-5 (IL-5). This antibody is constructed from human IgG4 heavy chains and human kappa light chains, and exhibits a predicted molecular weight of 150 kDa. For experimental control purposes, the appropriate isotype control is Human IgG4 kappa. This product is ideal for research applications focusing on the biological roles and regulatory mechanisms of IL-5 in immune responses and inflammatory processes.

Epacmarstobart (FSI-189; GS-0189) is a chimeric humanized monoclonal antibody of the IgG1κ subclass, specifically designed to target the mouse signal regulatory protein alpha (SIRPα). This antibody facilitates research into the modulation of immune responses, particularly in models studying phagocytosis inhibition by SIRPα signaling in macrophages and other phagocytic cells. Its humanized design minimizes immunogenicity, making it an ideal tool for prolonged studies in murine models.

Linclatamig is a humanized IgG1κ monoclonal antibody that specifically targets CD3E. For isotype control, Human IgG1 kappa Isotype Control is recommended. This antibody is designed for precise targeting, making it ideal for research applications focusing on CD3E-related pathways and immune responses.

Emiltatug is a human monoclonal antibody of the IgG1κ subtype that specifically targets VTCN1 (V-set domain-containing T-cell activation inhibitor 1). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

The Anti-MSPR/RON/CD136 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the MSPR/RON/CD136 receptor. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 145.74 kDa. For isotype control, researchers should use the Human IgG1 kappa Isotype Control. This antibody is essential for studies focusing on the biological functions and therapeutic targeting of the MSPR/RON/CD136 receptor in various cellular processes and disease states.

Cosibelimab (CK-301; TG-1501) is a fully human monoclonal antibody with high affinity for PD-L1, effectively inhibiting its interaction with PD-1. This antibody features a functional Fc domain, enabling it to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These mechanisms facilitate the targeted killing of PD-L1-expressing cell lines, including various lymphoma cells, making it a critical tool for research in oncology and immunotherapy.

Pidilizumab (CT-011) is a humanized IgG1k monoclonal antibody targeting PD-1. It functions as a DLL1 antagonist, offering significant potential for research into hematologic malignancies. This antibody is designed for specificity to PD-1, making it a valuable tool for studies focused on immune checkpoint pathways and their roles in cancer immunotherapy.

Anti-CLDN6 Antibody (AB1-11) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CLDN6. This antibody is comprised of an IgG1 heavy chain and a human kappa (huκ) light chain, and exhibits a predicted molecular weight of 78.42 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa, Isotype Control.

Remzistotug is a human monoclonal antibody of the IgG1κ subtype designed to specifically target PVRIG. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Durvalumab (MEDI4736) is a human monoclonal antibody targeting PD-L1. This antibody effectively inhibits the interaction of PD-L1 with its receptors PD-1 and CD80, demonstrating inhibitory concentrations (IC50) of 0.1 nM and 0.04 nM, respectively. Durvalumab's high specificity and potent binding affinity make it a valuable tool for research into checkpoint inhibition and immune response modulation.

Docaravimab is a monoclonal antibody specifically designed to target the G-III epitope of the Evelyn-Rockitniki-Abelseth (ERA) glycoprotein ectodomain. This antibody is utilized primarily in the study of Rabies, facilitating advanced research into the virus's pathogenesis and immune evasion mechanisms. Docaravimab serves as a vital tool for researchers aiming to understand and potentially mitigate the effects of the Rabies virus at the molecular level.

Disitamab (RC48-0) is a humanized monoclonal antibody specifically targeting the human epidermal growth factor receptor 2 (HER2). This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), including Disitamab vedotin. Disitamab exhibits high specificity and affinity for HER2, making it a valuable tool in targeted cancer therapy research, particularly for the treatment of HER2-positive tumors.

Izeltabart is a humanized antibody with high affinity for ADAM9, designed for use in antibody-drug conjugate (ADC) applications. This antibody facilitates the site-specific attachment of Maytansinoid-based DM21-C, a drug-linker conjugate, to create the ADC known as IMGC936. The DM21-C component consists of a Maytansinoid, which acts as a microtubule inhibitor, linked via a stable tripeptide. IMGC936 demonstrates pronounced cytotoxic effects on ADAM9-expressing human tumor cell lines and has shown significant antitumor efficacy in xenograft tumor models. This product is pivotal for research focused on targeted cancer therapies, particularly those exploring the therapeutic potential of ADCs in oncology.

Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody that specifically targets aggregated α-synuclein. This antibody is designed for use in research related to Parkinson's disease, offering potential insights into disease mechanisms and therapeutic interventions.

Anti-Siglec-2 / CD22 (NCI m972) is a humanized monoclonal antibody specifically designed to target CD22, a member of the Siglec family of lectins predominantly expressed on B cells. This antibody shows potential as a novel therapeutic agent for the treatment of B-cell acute lymphoblastic leukemia (BCP-ALL), offering targeted intervention in the disease pathology.

Danburstotug (IMC-001) is a human monoclonal antibody of the IgG1-lambda isotype, specifically targeting CD274, also known as PDL1 or B7-H1. This antibody functions as both an immunostimulant and an antineoplastic agent, making it applicable in the study of immune checkpoint pathways and cancer immunotherapy.

Gotistobart (ONC-392) is a humanized monoclonal antibody targeting CTLA-4, designed to enhance immunotherapeutic efficacy through the selective depletion of regulatory T cells (Tregs) within the tumor microenvironment. This antibody facilitates a targeted approach to modulate the immune system, potentially improving treatment outcomes in cancer immunotherapy.

Tarperprumig is a monoclonal antibody engineered to target both ALB (Albumin) and CFP (Complement Factor Properdin) through its unique composition of two linked heavy chain variable regions. This bifunctional antibody is designed for high specificity and affinity in binding to its target antigens, making it an ideal tool for research in protein interaction studies and immune response investigations.

Acimtamig (AFM13) is a bispecific innate cell engager targeting CD30 and CD16A. This therapeutic agent facilitates the selective cross-linking between natural killer (NK) cells, through CD16A engagement, and CD30-expressing tumor cells. The dual binding capability of Acimtamig enhances the cytotoxic potential of NK cells against targeted tumor cells, making it an invaluable tool for investigating the pathophysiology and potential treatments of peripheral T-cell lymphoma (PTCL).

Golimumab (CNTO-148) is a potent monoclonal antibody of the human IgG1 subclass that functions as a TNFα antagonist. It exhibits anti-inflammatory properties by inhibiting the production of interleukins IL-6 and IL-1β. The mechanism of action of Golimumab involves targeting and neutralizing tumor necrosis factor (TNF), thereby preventing inflammation and the associated degradation of cartilage and bone. Additionally, Golimumab demonstrates anticancer properties through the induction of cell apoptosis. This antibody is applicable in the research of rheumatoid arthritis, Crohn's disease, and various cancers, providing a valuable tool for both basic research and therapeutic development.

Tarextumab (OMP-59R5) is a fully human IgG2 monoclonal antibody designed to target and inhibit Notch2 and Notch3 receptors. This antibody exhibits potent anti-tumor activity by interfering with the Notch signaling pathway, which is often implicated in the regulation of cell differentiation, proliferation, and apoptosis. Tarextumab is primarily utilized in oncological research to explore therapeutic strategies against various cancers where Notch signaling plays a critical role.

Sonelokimab (ALX 0761) is a trivalent bispecific nanobody that incorporates camel-derived, humanized antibodies targeting IL-17F and IL-17A/F, along with antibodies specific to serum albumin VHH. This configuration enhances the plasma half-life of the molecule through its interaction with human serum albumin. Sonelokimab is primarily utilized in research focused on inflammatory conditions such as rheumatoid arthritis and psoriasis, offering a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these diseases.

Lumrotatug is a human IgG1 κ monoclonal antibody targeting CD38. For accurate experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.